title: [Priorisation in health-care; drug-reimbursement priorities in Hungary in 2004].
abstract: In our research we assessed the drug reimbursement of the National Health Insurance Fund Administration (NHIFA) in different ATC groups. We used the aggregated data of retail pharmacies in 2004, analysing separately the accentuated and elevated categories associated with medical indications. According to the 2004 data it was the drugs for cardiovascular; endocrine and metabolic disorders affecting the largest population and making the highest proportion of the total reimbursement. In addition, the turnover of some drugs for mental disorders was also significant. As for the number of patients in the cancer group it is much smaller, but as a result of the huge costs of their therapies these belong to the highest reimbursed categories as well. Without the special, separately financed category the annual drug subsidy was 257 bill. HUF, which totalled 423 bill. HUF on consumer price. The reimbursement of the NHIFA in the top 25 categories exceeded 177 bill. HUF. In the accentuated category the contribution of the NHIFA approximated 49 bill. HUF spent on the treatment of cancer, diabetic and some psychiatric disorders. In the elevated category based on health status the products of mental, digestive, bone and respiratory systems disorders were responsible for the highest turnover with more than 55 bill. HUF subsidy. Besides knowing the amount of reimbursement it is also important to be familiar with the size of affected, treated population. However in many cases we do not have any detailed, up-to-date Hungarian data, so the under-, or the possible overtreatment can hardly be analysed accurately.
authors.affiliation: Budapesti Corvinus Egyetem, Közszolgálati Tanszék, Egészség-gazdaságtani.
authors.forename: Krisztián
authors.initials: K
authors.lastname: Kárpati
authors.forename: Agnes
authors.initials: A
authors.lastname: Brandtmüller
authors.forename: István
authors.initials: I
authors.lastname: Májer
authors.forename: László
authors.initials: L
authors.lastname: Gulácsi
mesh_terms: D006292:Health Priorities / Q000639:trends*; D006814:Hungary; D004364:Pharmaceutical Preparations / Q000191:economics*; D012051:Reimbursement Mechanisms
chemical_list: D004364:Pharmaceutical Preparations